Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9529006 | 0.81 | MDM2 (0.47) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL8064436 | 0.81 | PIM1 (0.56) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL9525995 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL9754547 | 0.78 | MCL1 (0.55) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL7649493 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL7646365 | 0.77 | PDE5A (0.50) | KDM4EALDH1A1GAAGLAMDM2 | |
| SCHEMBL4474609 | 0.76 | MDM2 (0.62) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL7644788 | 0.75 | PDE5A (0.45) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL3479424 | 0.74 | HPGD (0.48) | KDM4EALDH1A1GAAGLAHPGD | |
| SCHEMBL11629754 | 0.74 | GUSB (0.48) | KDM4EALDH1A1GAAGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2139333-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008118414-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-0636142-B1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | disclosed |
| US-5721222-A | Heterocyclic ketones | ZENECA LIMITED (GB) | 1998-02-24 | — | — | US | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| US-5486529-A | Certain pyridyl ketones for treating diseases involving leukocyte elastase | ZENECA LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| EP-0636142-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021209-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | KDM4E 1920/4885ALDH1A1 3380/4885GAA 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.